Lisata Therapeutics (LSTA)

Executive Summary

Lisata Therapeutics is a clinical-stage pharmaceutical company developing innovative therapies for advanced solid tumors using its proprietary CendR Platform®, which enhances targeted drug delivery to tumors. The lead candidate, certepetide (LSTA1), is currently being evaluated in multiple mid-stage trials, including a Phase 2b study for pancreatic cancer and a Phase 2a study for cholangiocarcinoma. The company's technology aims to address the challenge of poor drug penetration in solid tumors by activating a transport pathway that allows co-administered drugs to enter tumor tissue more effectively. With a strong focus on difficult-to-treat cancers, Lisata has the potential to improve outcomes for patients with limited treatment options. However, as a clinical-stage company, it faces significant regulatory and development risks. The company is publicly traded under the ticker LSTA and has a market capitalization of approximately $29 million as of early 2026.

Upcoming Catalysts (preview)

• Q3 2026Phase 2b Data Readout for Certepetide in Pancreatic Cancer35% success
• Q4 2026Phase 2a Data Readout for Certepetide in Cholangiocarcinoma40% success
• TBDPotential Partnership or Licensing Deal for CendR Platform30% success